In Vivo Handling of Soluble Complement Fixing Ab/dsDNA Immune Complexes in Chimpanzees

Robert P. Kimberly,* Jeffrey C. Edberg,* Louis T. Merriam,* Sarah B. Clarkson,‡ Jay C. Unkeless,§ and Ronald P. Taylor‖

*The Hospital for Special Surgery, Cornell University Medical College, New York 10021; ‡Rosalind Russell Arthritis Research Laboratory, San Francisco General Hospital, San Francisco, California 94110; §The Department of Biochemistry, Mount Sinai School of Medicine, New York 10029; ‖The Department of Biochemistry, University of Virginia School of Medicine, Charlottesville, Virginia 22908

Abstract

We used soluble, C-fixing antibody/dsDNA IC to investigate immune complex (IC) handling and erythrocyte (E)-to-phagocyte transfer in chimpanzees. IC bound efficiently to chimpanzee E in vitro and showed minimal release with further in vitro incubation in the presence of serum in EDTA (≤ 15% with 1 h). These IC also bound rapidly to E in vivo (70–80% binding within 1 min) and did not show detectable release from E in the peripheral circulation after infusion in vivo (≤ 2% with 1 h). Despite such slow C-mediated release of IC from E, IC were rapidly stripped from E by the mononuclear phagocyte system (T50 for E–IC1500 = 5 min) without sequestration of E. Transfer of the chimpanzees with the anti-FcγRIII MAb 3G8 impaired the clearance of infused IC. This effect was most evident on the fraction of IC500 which did not bind to E and which presumably had captured less C3b (pre-MAb 3G8 T50: 45 min vs. post-MAb 3G8 T50: 180 min). With IC bound in vitro to E before infusion, anti-FcγRIII MAb treatment led to significant amounts of non-E bound IC detectable in the circulation. Thus, the anti-FcγRIII MAb appeared to interfere with the ability of fixed tissue mononuclear phagocytes to take up or retain IC after their release from E. Both rapid stripping of IC from E, despite slow complement-mediated release of IC from E in the peripheral circulation, and blockade of IC clearance with anti-FcγRIII MAb indicate that the interaction of IC with the fixed tissue phagocyte occurs qualitatively different mechanisms than the interaction of IC with E. Fcγ receptors appear to play an important role in the transfer and retention of IC by the phagocyte.

Introduction

Altered handling of immune complexes (IC)1 is an important factor in the development of IC mediated disease. In experimental animals, saturation of clearance mechanisms or prolongation of IC circulation times by various techniques can lead to increased IC deposition in target organs (1–6). The mononuclear phagocyte system (MPS) of liver and spleen provides the primary mechanism for IC disposal (5–9). Circulating IC are removed by binding to receptors for the Fc portion of IgG and receptors for C3 fragments on the fixed tissue mononuclear phagocytes of this system (5, 8–12). Recent work by Hebert (13–16) and others (17–20), however, has emphasized the importance of complement (C) receptor type 1 (CR1)-mediated binding of circulating C-fixing IC to human and nonhuman primate erythrocytes (E). These observations suggest that E can act as a “buffer,” which can bind C-fixing IC by way of CR1 and may decrease the probability of deposition of these IC in target tissues (21, 22).

CR1-mediated E binding in primates (and a comparable platelet binding reaction in nonprimates [23–25]) leads to the possibility that E may serve not only as a buffer by partitioning circulating IC to an E-bound pool but also as a delivery system, or “shuttle,” which presents IC to the MPS for removal (26). From the perspective of an “erythrocyte shuttle,” several questions become evident: (a) what are the determinants of the efficiency of binding to E; (b) is binding to an E a prerequisite for removal by the MPS; (c) are the rates of E-bound IC and non-E bound IC different; and (d) what are the mechanisms of transfer of IC from E to the MPS? Some information regarding these questions is available. For example, among the determinants of IC binding to E via CR1, the ability to fix C, the amount of C3b capture and the spatial organization of the captured C3b are important (25, 27). Binding to E is not a prerequisite for efficient handling by the MPS (14, 25, 28). Both model IC with rapid C-mediated release from E (tetanus/anti-tetanus toxoid and BSA/anti-BSA in vivo [13, 18] and in vitro [29, 30]) and model IC with slow C-mediated release from E (Ab/dsDNA in vivo [24, 25] and in vitro [31]) are cleared quickly by the MPS. These observations suggest that E binding may not fundamentally affect the rate of removal of IC by the MPS and that other properties of the IC or factors in the MPS must be significant.

To investigate the properties of the immune adherence reaction in IC handling in primates and to probe the nature of the E-to-phagocyte (MΦ) transfer mechanism, we performed a series of model IC infusion studies in chimpanzees. As a model IC system we used Ab/dsDNA IC because this antigen-antibody system is relevant to autoimmune disease (32, 33), these model IC fix C efficiently and bind to E CR1 (34–36), and their slow release from E allows for direct investigation of potential E sequestration during the IC transfer process. In addition to conventional clearance studies, we used anti-Fcγ receptor MAb infusions to probe the role of Fcγ receptors in the removal of soluble IC from the circulation by the MPS. Our data indicate that C-fixing Ab/dsDNA IC bind rapidly to primate E, that IC are transferred to MΦ without sequestration...
of E or apparent release of IC into the circulation, and that an FcγR on the Mcϕ participates in the uptake of IC. These data, demonstrating that the transfer mechanism is much faster than C (Factor I) mediated spontaneous release of IC from E and that FcγRIII blockade alters IC uptake, indicate that the interaction of IC with fixed tissue phagocytes involves qualitatively different mechanisms than the interaction of IC with E.

Methods

Animals. Healthy adult chimpanzees (Pan troglodytes), maintained at the New York University Laboratory of Experimental Medicine and Surgery in Primates (LEMSIP), Tuxedo Park, NY, were used to study the handling of Ab/dsDNA IC. Previous work has demonstrated that neutrophils from chimpanzee, but not from seven other nonhuman primate species, bind MAb 3G8 (12), which recognizes FcγRIII in humans (37). All in vivo experimental procedures were performed at LEMSIP with animals maintained under light ketamine anesthesia. All protocols were approved by the Institutional Animal Care and Use Committee of LEMSIP.

Preparation of antibodies. The 7S IgG fraction of an SLE plasma (plasma Ma), which contains high titer nonprecipitating anti-dsDNA antibodies, was prepared as previously described (25, 35). The IgG anti-dsDNA antibodies isolated from this plasma form soluble, C-fixing IC with dsDNA that bind to CR1 on human E (31, 36). The biophysical and immunological properties of these IC have been extensively characterized both in vitro and in vivo in a number of animal systems (24, 25, 27, 28, 31–34).

3G8, a murine IgG1 MAb recognizing human FcγRIII, was prepared by Damon Biotechnology (Needham Heights, MA). MOPC 21, a murine IgG1 myeloma protein, was prepared as previously described (12). Fab fragments were prepared by digestion with papain-Sepharose (Sigma Chemical Co., St. Louis, MO) and purified by passage over protein A-Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) at pH 8.3 and by molecular sieve chromatography with a column of TSK 3000 (LKB Instruments, Inc., Rockville, MD). Proteins were >95% pure, and Fab fragments contained no detectable heavy chains, as judged by silver stain of SDS-PAGE analytical gels. Preparations used for infusions were sterile and contained <0.25 ng endotoxin/mg of total protein, as determined by the Limulus amebocyte assay (Associates of Cape Cod, Woods Hole, MA).

Preparation of radiolabeled dsDNA. Iodinated dsDNA was prepared and characterized before each experiment as previously described (24, 25). Briefly, PM2 dsDNA, either intact (9,000 bp) or sonicated (800 bp), was radiolabeled with 125I-dCTP (New England Nuclear, Boston, MA) by nick translation. The sizes of the resulting 125I-labeled dsDNA preparations were 1,500±200 bp (“large dsDNA”) and 500±100 bp (“small dsDNA”), respectively, as determined by 3.5% PAGE. The radiolabeled preparations ranged from 1,000 to 2,000 cpm/ng sp act. The 125I-dsDNA preparations were 80–92% double-stranded as assessed by S1 nuclease digestion (Bethesda Research Laboratories, Gaithersburg, MD) and >95% precipitable in 5% TCA.

Preparation and characterization of soluble immune complexes. The 7S IgG anti-dsDNA was titrated with each DNA preparation to determine the amount of antibody required for maximal C-mediated binding (34). These IC give >90% binding in the Farr assay (38). To insure that the dsDNA was saturated with anti-DNA antibodies, soluble IC for the in vivo experiments were prepared at a two- to threefold higher Ab/dsDNA ratio (27, 35). IC made with dsDNA of 500 bp are typically 50–100 S in size (34).

For experiments with IC released in vitro from chimpanzee E (see below), the relative sizes of the dsDNA antigen in different IC preparations were checked by submarine gel electrophoresis in 1% low endoosmotic agarose. Gels were visualized directly under ultraviolet light and then autoradiographed with Kodak XAR film. No differences in the size of the dsDNA antigen from the initial IC preparation relative to that from the released preparation could be detected.

Preparation of erythrocytes for in vitro and in vivo use. E. isolated from heparinized whole blood, were washed twice with PBS-10 mM EDTA and three times with PBS containing 0.15 mM CaCl2 and 0.5 mM MgCl2 (PBS+). Chromium labeled E were prepared by incubating an aliquot of 25% (vol/vol) autologous E with 0.5 mCi of 51Cr for 30 min at 37°C. The radiolabeled E were subsequently washed three times and resuspended at a concentration of 25% in PBS+.

Immune complex binding to primate erythrocytes in vitro. For quantitative binding of IC to chimpanzee E or human E in the presence of autologous serum C, washed E were incubated with saturating concentrations of freshly prepared IC for 20 min at 37°C (34). This procedure typically yielded >85% bound and 10–20 IC per E. After one wash with PBS to remove unbound IC and the addition of fresh serum in EDTA (as a source of C), the release reaction was assessed by the time-dependent appearance of unbound IC in the supernatant (39). To assess possible C-independent binding to chimpanzee E, aliquots of E, 7S anti-DNA IgG and labeled dsDNA were incubated with heat-inactivated serum. Negligible binding (<10%) occurred under these conditions. Similarly, 125I-dsDNA mixed with fresh serum C did not bind to E in the absence of antibody.

Experimental protocols for handling of soluble IC. For each in vivo experiment IC were freshly prepared according to one of four protocols from titered stocks of anti-dsDNA IgG and radiolabeled dsDNA. (a) For direct in vivo infusions of soluble C-fixing IC, predetermined amounts of 7S IgG anti-dsDNA and 125I-dsDNA were mixed and incubated for 1 h at 37°C just before intravenous injection. (b) For IC bound in vitro to autologous E, freshly prepared soluble IC were incubated for 20 min at 37°C with a 25% suspension of 51Cr-labeled chimpanzee E and fresh autologous serum C. After one wash with PBS, these “IC-loaded” E were injected immediately. (c) To obtain “released complexes” an aliquot of “IC-loaded” E was further incubated with fresh autologous serum as a C source and actively mixed for 3–4 h at 37°C. The resultant supernatant, containing the released IC, was harvested and injected intravenously. Under these conditions this procedure yielded 40–60% release of IC from E. (d) Finally, IC were prepared in vitro to contain large amounts of human C3d4g fragments (“partial d4g IC”) as previously described (31). Ab/H-dsDNA IC were opsonized with human C and allowed to bind to human E. The IC were then released from the E by overnight incubation in serum at 37°C. These released IC (containing C3d4g) were treated with DNase and then 50% SAS to recover the C3d4g-containing anti-dsDNA IgG. These Ab formed IC with fresh dsDNA (as detected in the Farr assay) that did not bind significantly to human E in the presence or absence of fresh human C (typically <25%). This IgG preparation was then used according to protocol a.

The IC were injected into an antecubital vein in <5 s. Blood samples (5.0 ml) were then drawn from the opposite arm every 30 s in initial experiments (every minute in later experiments) for the first 3 min, then at 5, 7.5, 10, 20, 30, and 60 min. Saline or MAb 3G8 (0.8 mg/kg) was then infused over 30 min and a second clearance study with an identical protocol was performed. Initial experiments indicated that the first study did not alter subsequent clearance studies (Fig. 5 A; reference 12).

Each 5.0-ml sample of blood was immediately heparinized, put on wet ice, and centrifuged at 2,000 rpm for 4 min. The cell pellet, containing both E and leukocytes, was rapidly resuspended in icec PBS, centrifuged again, and separated from the supernatant. This processing of the pellet was complete within 10 min. As a control for time-dependent release of IC from E after phlebotomy but before completed sample processing, selected duplicate specimens were set aside for 30 min on wet ice and then processed in the usual fashion. No detectable release of the bound IC was observed. Finally, selected blood specimens were separated on single density Percoll to confirm that the IC were bound to the E (13, 19).

The supernatant harvested from the washed cell pellet was combined with the initial icd plasma supernatant for each sample. Aliquots (1.0 ml) were mixed with one-half volume of 15% TCA at room temperature to precipitate intact dsDNA (immune complexed or free).
Saturated ammonium sulfate (SAS) was added to a second 1.0-ml aliquot for a final concentration of 40% vol/vol on wet ice to precipitate immune complexes \[^{125}\text{I}\]-dsDNA. After centrifugation at 5,000 rpm for 20 min, the supernatants and precipitates were harvested and counted separately. A third measured aliquot of the plasma plus wash supernatant was saved and counted directly.

Experimental protocol for handling of IgG-opsonized erythrocytes (12). Chimpanzee E were chromium labeled and sensitized with an amount of chimpanzee anti-AcBcDc antiserum sufficient to yield 20,000 molecules of IgG per E. After intravenous injection of opsonized cells, blood samples were obtained from the opposite arm at 3, 5, 15, 30, 60, 90, and 120 min. A second study with freshly opsonized E was performed after infusion of MAB 3G8.

Data analysis in the soluble IC experiments. For each blood sample the counts for each fraction (cell pellet; TCA supernatant and TCA pellet; SAS supernatant and SAS pellet; unaltered plasma) were combined to derive total sample counts. The sum of both TCA fractions, both SAS fractions and the unaltered plasma fraction was designated "non-E bound"; the cell pellet was designated "erythrocyte bound" since Percoll density gradient analysis indicated that essentially all counts were associated with the E fraction. The non-E bound but TCA precipitable IC were calculated by the following formula: [TCA pellet/ (TCA supernatant + TCA pellet)] \times total non-E bound counts. The same calculation was used to determine the SAS precipitable non-E bound IC. The total TCA (or SAS) precipitable counts were defined as the sum of both the TCA (SAS) precipitable non-E bound counts and the E bound counts; this calculation assumes that all E bound counts would be precipitable in solution (24, 25). For the double label experiments, absolute counts per minute were corrected for spectral overlap of the two isotopes.

For clearance studies, each curve represents the mean (±SD) of all animals for each experimental condition. The clearance curves, both before and after MAB 3G8 infusion, were analyzed for the time required for the clearance of 50 and 75% of the E bound (or non-E bound TCA precipitable) counts (T\(_{50}\) and T\(_{75}\), respectively) relative to the counts present at 1 min in the appropriate fraction. In addition, we calculated the recovery of counts in the circulation based on the total counts infused and on the estimated blood volume of the animal. Typically, at 1 min, 75–85% of the total infused counts were present in the circulation.

Results

Antibody/dsDNA complexes in the chimpanzee model system

Binding of IC to chimpanzee erythrocytes in vitro. Human 7S IgG anti-DNA/dsDNA IC made with large DNA (~1,500 bp [IC\(_{1,500}\)]) bind efficiently to human E in a C-dependent fashion (31, 34–36). Similarly, > 80% of model IC made with larger DNA (~3,000 bp) bind E from rhesus monkey when assayed in vitro and tested in vivo (19). To confirm C-mediated IC binding to chimpanzee E, IC made with \[^{125}\text{I}\]-labeled dsDNA (both IC\(_{1,500}\) and IC prepared with small dsDNA of ~500 bp [IC\(_{500}\)]) and \[^{3}\text{H}\]-labeled intact PM2 dsDNA were incubated with autologous serum as a source of C and an excess of E for 20 min at 37°C. Efficient binding to chimpanzee E was evident for all three dsDNA preparations (Table I). Only 15% of the IC were released from chimpanzee E within 60 min after the addition of fresh C in EDTA. These data indicate that IC containing large dsDNA IC bind efficiently to chimpanzee E in vitro and in addition that the in vitro C-mediated release reaction for these large IC from chimpanzee E is slower than it is for human E.

Partitioning of soluble IC to erythrocytes in vivo. Large, soluble antibody/dsDNA IC (IC\(_{1,500}\)) showed rapid binding to the chimpanzee E after intravenous infusion. More than 50% of circulating IC were bound within 15 s and ~70% were bound by 1 min, whereas native DNA (both ~1,500 bp and ~500 bp) showed minimal binding (~6% to E (Fig. 1). These findings are consistent with observations of rapid binding to E of similar Ab/dsDNA IC in baboons (16) and in rhesus monkeys (19), of very large anti-BSA/BSA IC in baboons (13), and of tetanus/antitetanus toxoid IC in humans (18).

In attempts to generate IC that would not bind to the E in vivo, we decreased the size of the dsDNA (34), used IC harvested from E after serum-mediated release (31), and generated IC partially opsonized with the human C degradation.

Table I. Binding of Ab/dsDNA IC to and release from Human and Chimpanzee E In Vitro

<table>
<thead>
<tr>
<th>Size of dsDNA</th>
<th>% Bound Buffer</th>
<th>Serum/EDTA</th>
<th>% Bound Buffer</th>
<th>Serum/EDTA</th>
</tr>
</thead>
<tbody>
<tr>
<td>9000 bp</td>
<td>85%</td>
<td>15%</td>
<td>90%</td>
<td>&lt;5%</td>
</tr>
<tr>
<td>1500 bp</td>
<td>45%</td>
<td>ND(^\text{a})</td>
<td>ND</td>
<td>85%</td>
</tr>
<tr>
<td>500 bp</td>
<td>&lt;10%</td>
<td>ND</td>
<td>ND</td>
<td>50%</td>
</tr>
</tbody>
</table>

\(^\text{a}\)Results are representative of experiments performed on two or more different donors for both chimps and humans. SD for values are ±5%. In all cases, homologous serum was used for opsonization and release.

\(^\text{b}\)Percent release of IC (after maximal E binding) upon the addition of fresh autologous serum in EDTA (or buffer) for 1 h at 37°C as described in Methods. Slightly more release of IC from chimpanzee E was evident at 2 h.

\(^\text{c}\)Not done.

*Figure 1. Binding of antibody/d\[^{125}\text{I}\]-dsDNA IC to E in vivo. The mean percent (±SD) of IC bound to E is shown at several different time points. IC\(_{1,500}\) (○) (n = 4 animals), showed peak binding at 60 s. IC\(_{500}\) (n = 8; □), serum released IC\(_{1,500}\) (n = 2; ▪), partial-dg IC\(_{1,500}\) (n = 4; △) and free dsDNA (both 1,500 bp and 500 bp) (n = 6; □) values are shown for 60 and 120 s (see Methods for preparation of ICs). 60-s values were within 5% of absolute peak values for all IC except the partial-dg IC\(_{500}\) which showed a difference between 60- and 120-s values (44.0±7.7 vs. 54.1±5.8%; P < 0.01) and a peak percent E binding (60.2%) at ~7.5 min.
product C3d,g (partial-d,g IC; [31]). The IC500 demonstrated binding to the E comparable to the IC prepared with the larger dsDNA (Fig. 1). Similarly, IC released in serum and the partial-d,g IC became opsonized with C in vivo as they were 62% and 54% E-bound, respectively, 2 min after infusion. The binding of these latter two IC preparations to E in vivo is somewhat in contrast to the in vitro human model. Preliminary evidence with anti-CR1 MAb E11 suggests that chimpanzee E have two to three times more CR1 sites than human E and that this may account for the higher IC binding. Since all of these IC were able to bind to chimpanzee E in vivo, we emphasized the IC500 for soluble IC infusions with concomitant anti-FcγRIII MAb administration. Both the released IC and the partial-d,g IC probably contain larger quantities of bound C3 degradation products which could influence IC removal by the MPS by other C receptors (CR2, CR3, or CR4 [40]).

Clearance of soluble, infused immune complexes. To test the in vivo behavior of both bound and non-E bound IC we infused several different types of soluble Ab/dsDNA IC. Initial experiments with free 1,500 bp and 500 bp dsDNA demonstrated that free DNA does not bind to E (Fig. 1) and is cleared from the circulation with an initial half-time of 10–15 min (Fig. 2A). This clearance rate is substantially slower than that found in nonprimates (half-time of 1–2 min; [19, 25]) but is comparable to that found in other primates (16, 19). Formation of IC with dsDNA altered the handling of the DNA. Most IC1,500 became bound to E in vivo and were cleared more rapidly than free DNA alone while non-E bound IC were cleared more slowly than free DNA alone. IC500 showed slower clearance, whether E-bound or non-E bound, than free DNA (Fig. 2, B and C). Interestingly, the clearance rate of E-bound IC1,500 was slower when soluble IC1,500 was infused directly than when IC1,500 was bound to E in vitro before infusion (see Fig. 2B and Fig. 3A). This observation suggests that loading of E with IC may continue over time after soluble IC infusion and lead to an apparently slower clearance rate for E-bound IC.

Values are calculated as a percentage of total counts at 1 min (mean±SD). SAS precipitable non-E bound counts show an analogous pattern with a high correlation to the TCA results (r = 0.79). In the absence of anti-FcγRIII, TCA precipitable, non-E bound counts were ≤ 1% of total 1 min counts during the first 10 min and increased to 4–5% by 30–60 min. In contrast, after anti-FcγRIII infusion, there was no increase above baseline in the TCA precipitable fraction throughout the 60 min of study.

**Figure 2.** Clearance of Free DNA and antibody/dsDNA IC. The clearances of TCA precipitable 125I-dsDNA (A) in vivo E-bound IC (B) and TCA precipitable IC in the non-E bound plasma fraction (C) are represented as the mean percent of counts remaining relative to counts determined at one min. For dsDNA1,500 (n = 4 animals) and dsDNA500 (n = 2), TCA precipitable counts (intact dsDNA comprised > 90% of all counts; there was no increase in the percentage of soluble counts over the course of the experiment. With both IC1,500 (n = 2) and IC500 (n = 4) there was a strong correlation between values for TCA precipitable (immune complexed or free) and SAS precipitable counts (immune complexed 125I-dsDNA) in the non-E bound fraction (r = 0.97 and r = 0.95, respectively) and only the TCA precipitable counts are shown for simplicity. TCA precipitable non-E bound counts represented 24.3±9.5% (mean±SD) of total counts at 1 min while TCA nonprecipitable, non-E bound counts were 6.1±1.9% of that total. At 30 min these values were 15.2±4.5% and 5.8±1.9% of the total counts at 1 min, respectively; at 60 min they were 9.1±3.0% and 5.6±1.8%, respectively.

**Figure 3.** Handling of IC1,500 pre-bound to E in vitro. (A) The clearance of IC1,500 prebound to E in vitro. The baseline clearance is shown with open circles while the clearance after infusion of anti-FcγRIII MAb is shown by the closed circles (n = 2). Data are presented as the percent of counts remaining relative to one min (mean±SD). (B) The appearance de novo of TCA precipitable non-E bound counts in the peripheral circulation under each condition (baseline in open circles [n = 4]; after anti-FcγRIII MAb in closed circles [n = 2] is represented.)
Disposition of in vitro erythrocyte bound antibody/dsDNA immune complexes. In several IC model systems, IC release rapidly from E after initial C-mediated binding. Both anti-BSA/BSA and tetanus/antitetanus toxoid IC show a rapid return to fluid phase in vitro (29, 30). This rapid release has also been sought and demonstrated in vivo with tetanus/antitetanus toxoid IC (18). Ab/dsDNA IC do not show rapid release in vitro (Table I), and therefore, experiments were designed to test for the occurrence of the release reaction in vivo. IC were bound to autologous E in vitro and these IC-loaded E alone were infused (Fig. 3A, open circles). No detectable release of IC into a non-E bound fraction was found in the circulation (<1% during the first 10 min and <2% over 1 h; Fig. 3B, open circles).

Given the lack of detectable release of Ab/dsDNA IC from E into the circulation, we tested the possibility that these IC-opsonized E would be sequestered by the MPS like E opsonized with anti-E IgG (12). Previous investigators attempting to address this question have looked for a change in the total body E mass rather than at the specific fate of those E opsonized with IC (13). Using double radiolabel techniques we examined the fate of the 125I-labeled E opsonized with 10–20 125I-labeled IC per E. Fig. 4 clearly demonstrates that the 125I-labeled E are not removed from the circulation while the 125I-labeled IC are rapidly stripped from the E by the MPS.

Role of FcγRIII in immune complex handling

FcγRIII (CD16) has been proposed as an Fcγ receptor that might participate in IC binding by the MPS. FcγRIII, defined by MAb 3G8 and other anti-CD16 MAb, is present in the red pulp of human spleen and in human liver sections (12,41; Fleit, H. B., personal communication). The CD16 epitope recognized by the MAb 3G8 is also present in a pattern typical for Kupffer cells in chimpanzee liver sections (12). The role of FcγRIII in the handling of IgG coated E has been examined in the chimpanzee. Chimpanzee E, opsonized in vitro with anti-chimpanzee E IgG (20,000 molecules of IgG per E), are removed from the circulation with a T50 of 70 min (Fig. 5D, open circles). After infusion of 3G8 IgG, 0.5 to 1.0 mg/ml, the clearance of these opsonized E is significantly prolonged (Fig. 5D, closed circles and reference 12). Since these studies indicated that FcγRIII plays an important role in the uptake of this Fc-mediated probe, we explored the impact of infusions of MAb 3G8 IgG and Fab on the handling of both IC1,500 prebound to E in vitro and on IC300 infused as free IC (not prebound).

Effect of anti-FcγRIII on IC loaded onto E before infusion. IC1,500 bound to chimpanzee E in vitro were cleared very rapidly after intravenous infusion (initial T50 of 5 min, Figs. 3A and 4). Since control studies with infused saline showed that neither ketamine anesthesia nor a prior clearance study prolonged the clearance of additional soluble IC (Fig. 5A), additional studies with IC1,500 prebound to E in vitro were performed. Infusion of MAb 3G8 IgG, 0.8 mg/kg, did not alter the earliest phase of the curves but did induce a modest impairment of IC1,500 removal after 7.5 min (Fig. 3A, closed circles). More striking, however, was the appearance of significant amounts of both circulating non-E bound TCA precipitable and non-E bound SAS precipitable IC after anti-FcγR MAb infusion. In contrast to the pretreatment experiments (Fig. 3B, open circles), clearly measurable free IC1,500 were apparent at every time point after MAb infusion (Fig. 3B, closed circles). This phenomenon is unlikely to be due to Factor I-mediated release of IC from E in the periphery (due to prolonged circulation) since it was evident during the first 7.5 min both when the pre- and posttreatment E-bound IC clearance curves were superimposable. Rather, it would appear that the anti-FcγR MAb was interfering with the ability of fixed tissue mononuclear phagocytes to take up and/or retain large C-fixing IC1,500 after their release from E.

Effect of anti-FcγRIII on infused soluble IC. Infusion of MAb 3G8 IgG (0.8 mg/kg), or MAb 3G8 Fab (0.6 mg/kg) did not alter the earliest phase of the in vivo E-bound IC1,500 clearance curve but did induce a modest impairment of removal after 7.5 min (Fig. 5B and C, respectively). However, when the non-E bound TCA precipitable IC500 were examined, it can be seen that MAB 3G8 IgG did produce a large impairment in clearance (Fig. 5E). When MAB 3G8 Fab was infused, no consistent change in the handling of the non-E bound IC fraction was seen (Fig. 5F). We attribute this observation to unexplained factors since one animal in this experimental pair showed an acceleration of clearance. The other animal showed a significant prolongation in the clearance of the non-E bound IC fraction after MAB 3G8 Fab infusion (pre-MAb 3G8 T 50 = 80 min, post-3G8 T50 = 200 min) similar to that induced by MAB 3G8 IgG.

Discussion

Recent investigations have focused on E CR1 and the role of the immune adherence reaction, originally described in 1953 by Nelson for IC (42), in the handling of circulating IC. A number of studies have carefully documented decreased numbers of CR1 on E from patients with autoimmune disease (43–45) and have shown decreased binding capacity for IC by such E even in the face of large E CR1 excess (46). While directing attention to the potential for E to partition IC into a bound pool unavailable for tissue deposition, these studies.
bound IC\textsubscript{500}, after intravenous infusion of soluble IC\textsubscript{500}, was also slowed by anti-Fc\textgamma{}RIII MAb IgG and Fab (n = 2, each condition). The T\textsubscript{50} increased from 45 min to \sim 180 min with intact IgG. T\textsubscript{15} was not reached during the period of observation. In the Fab experiments, one animal showed accelerated clearance after MAb (unlike all other animals) thus leading to a minimal average effect on clearance. The other animal showed a pronounced MAb effect (T\textsubscript{50} increasing from 80 to 200 min).

have not addressed the mechanism of IC uptake by fixed tissue phagocytes. To explore some of the mechanisms involved in IC uptake, both for the transfer of E-bound IC to M\textphi and for the direct uptake of non-E bound IC by M\textphi, we performed a series of model IC infusion studies in chimpanzees. Our data indicate that transfer from E to M\textphi proceeds rapidly and much faster than Factor I-mediated release of IC from E both in the circulation and in vitro (Fig. 4, Table I). Blockade of the ligand binding site of Fc\textgamma{}RIII alters the handling of E-bound and non-E bound IC (Fig. 5). Taken together, these data indicate that the interaction of IC and E-IC with fixed tissue phagocytes involves qualitatively different mechanisms than the interaction of IC with E CR1.

The Ab/dsDNA IC were chosen as a model antigen-antibody system because these IC are relevant to autoimmune disease (32, 33), they have well-characterized immunological properties and their behavior has been studied in human, primate, rabbit, and mouse models (24, 25, 27, 28, 31, 34–36). These IC fix C efficiently, bind avidly to primate E via CR1 and release slowly from human E in the presence of Factor I (Table I). These Ab/dsDNA IC are unlike previously studied BSA/anti-BSA and tetanus/antitetanus toxoid IC which show more rapid release from E in the presence of Factor I (18, 29, 30). This important difference in the kinetics of release precludes the use of these latter two model IC systems for the investigation of several critical questions including sequestration of IC-opsonized E by the MPS and retention of IC by M\textphi Fc receptors.

Specific examination of the Ab/dsDNA IC model system in chimpanzees revealed in vitro properties analogous to those documented in humans and other animals (Table I). When infused in vivo (Figs. 1 and 2), these model IC behaved similarly to those infused into baboons, rhesus monkeys, rabbits, and mice (16, 19, 24, 25, 28). As in the baboon, E-bound IC\textsubscript{500} were cleared more rapidly in chimpanzee than free dsDNA alone while E-bound IC\textsubscript{500} were cleared more slowly than free dsDNA. The higher binding levels of IC to chimpanzee E (and slower release in vitro) probably reflect a higher density of CR1 per E as suggested by increased levels of binding of monoclonal anti-CR1 antibody E11. Efficient uptake of non-E bound IC occurred for both types of IC. Interestingly, free dsDNA alone was cleared much more slowly in chimpanzee (and in other primates [16, 19]) than in several nonprimate species (19, 25, 47).

**Mechanism of IC transfer from erythrocytes to M\textphi**

IgG-opsonized E are sequestered by the MPS in both humans (10) and chimpanzees (12). Given the slow Factor I-mediated release of Ab/dsDNA IC from chimpanzee E, we examined whether a similar sequestration of IC-opsonized E would occur. Previous experimental approaches to this question have been confounded by the use of a model IC probe with rapid release from E and by measurement of changes in total body E mass rather than by monitoring of the fate of the specific E loaded with IC. Using double radiolabel techniques and E loaded with IC, we could independently determine the dispo-
Figure 6. Schematic representation of IC transfer. Two alternative mechanisms for the intrahepatic transfer of IC from E to Mφ are presented. In mechanism A IC is released from E in the hepatic environment before engagement by receptors on the phagocyte. This release could involve a Factor I-mediated process (qualitatively distinct from the peripheral), proteolytic cleavage (48) or some other mechanism. In B, E-IC are directly engaged by phagocytes as suggested by Robineaux (55). This alternative implies that release of IC from E occurs as a secondary consequence of initial engagement of the E by the Mφ.

<table>
<thead>
<tr>
<th>Peripheral Circulation</th>
<th>Mononuclear Phagocytic System</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Entry</td>
</tr>
<tr>
<td>A</td>
<td>E</td>
</tr>
<tr>
<td></td>
<td>IC</td>
</tr>
<tr>
<td>B</td>
<td>E</td>
</tr>
<tr>
<td></td>
<td>IC</td>
</tr>
</tbody>
</table>

The mechanisms underlying this highly efficient stripping of E, however, remain incompletely defined. It has been proposed that the transfer of IC from E to Mφ involves the proteolytic cleavage of the E CR1 (48, 49). Such cleavage would have to be very rapid, and unless E CR1 has a unique susceptibility to such cleavage, CR1 expressed on all cells in the hepatic environment would be susceptible to this proteolytic mechanism. Alternatively, if the mechanisms include high local concentrations of Factor I and more effective cleavage of C3b, then receptors for C3b (CR1) on the Mφ must not play an important role in IC uptake. A much higher density of CR1 on the Mφ could be invoked to explain a shift in the reversible C3b-mediated binding from the low density E-CR1 to much higher density Mφ CR1. However, this explanation would appear more appropriate for model IC with faster release reactions in vivo. As demonstrated in Fig. 3 B (open circles), this release reaction does not occur with this Ab/dsDNA IC.

Several other receptor systems are available to mediate transfer to and uptake by mononuclear phagocytes. In addition to C receptors for bound C3 degradation products (CR2, CR3, CR4 [40]), several different families of Fc receptors have been characterized (50). These receptors include the high affinity FcγRII found on mononuclear phagocytes and interferon-γ-stimulated neutrophils (51–53), the low affinity FcγRIII found on most lymphoid and myeloid cells including platelets (54), and FcγRIII, a low affinity receptor found on Mφ, neutrophils and natural killer cells (37). This latter receptor, which preferentially binds multivalent ligands, has been proposed as an Fc receptor that participates in IC binding. Indeed, previous data indicate a significant role for FcγRIII in the handling of IgG-opsonized E (12). Accordingly, we investigated the role of FcγRIII in the handling of antibody/dsDNA IC which fix C efficiently and engage CR1 (on E) rapidly and with high affinity.

**Role of FcγRIII in IC clearance**

Infusion of anti-FcγRIII MAb 3G8, both as intact IgG and as Fab fragments, induced a modest impairment in the clearance of E-bound model IC (Fig. 3 A and Fig. 5). More apparent was the effect on the handling of non-E-bound IC, which may have captured less C3b (Fig. 5). These observations indicated that blockade of the ligand binding site of FcγRIII on fixed tissue Mφ interfered with the uptake of model IC. However, these data could not distinguish between interference with initial engagement of the IC by the Mφ and impairment of retention of IC after initial engagement.

An approach to this question can be made using IC bound to E in vitro to formulate the experimental framework (Fig. 6). One model of IC transfer would require rapid release of the IC from the E upon entry of the E-IC into the hepatic environment followed by engagement of the IC in a non-E-bound state by the Mφ (Fig. 6 A). However, no evidence for Factor I-mediated release of IC from E could be found in our experiments (Fig. 3 B). If one assumes that the Mφ encounters the IC directly in the E-bound state (Fig. 6 B) as suggested by the work of Robineaux more than 25 years ago (55), then rapid stripping would occur as a consequence of physical engagement of the E-IC by the Mφ. If blockade of FcγRIII interferes with this engagement, the clearance of E-bound IC would be prolonged without the generation of stripped, non-E bound IC. If blockade of FcγRIII did not interfere with engagement but did impair Fc receptor-mediated retention of the IC on the Mφ cell surface, this would lead to stripped, non-E bound IC in the circulation. In order to examine this specific question, we looked for the appearance of TCA-precipitable and SAS-precipitable IC (bound to E in vitro) in the circulation after MAb infusion (Fig. 3). At every time point, both when the preand posttreatment E IC clearance curves were superimposable and when they were divergent, significant levels of non-E bound IC1,500 appeared in the circulation after MAb 3G8 infusion. Given the "direct contact" model of transfer, it would appear that retention of the IC after stripping from the E (and presumed chemical modification of the IC [29] and/or E-CR1 [48, 49]) by the Mφ is impaired by Fc receptor blockade. This postulated mechanism, which implies impaired retention and subsequent release of the IC, is reminiscent of the release reaction reported by Atkinson, Frank, and colleagues for sequestration and release of C-opsonized E (9). Of course, these considerations do not exclude participation of Fc receptors in initial engagement of the IC by the Mφ in either model.

The handling of soluble IC by Mφ appears to involve an intricate interaction between the IC and several different receptor systems. The equivalent binding of IC1,500 and IC500 to CR1 on chimp E and their unequal binding to and clearance by Mφ argues for significant qualitative differences in Mφ binding of IC compared to CR1-mediated E binding of IC. The relative contribution to clearance of the IC by each receptor system will depend upon the specific immunochernical properties of the IC. For example, IC that fix C but do not capture sufficient C3b (27) will be handled more by Fc receptors. The number of expressed receptors, their spatial grouping (56) and their intrinsic properties (perhaps reflecting allelic polymorphisms; Salmon, J. E., J. C. Edberg, and R. P. Kimberly. Manuscript submitted for publication.) will also contrib-
ute to the relative role of each system. Genetically determined differences in receptor structure (57, 58), expression (59) and function (60, 61), and acquired differences in expression and display may be important in determining net function. For example, patients with SLE show both defects in C and Fc receptor dysfunction which can vary with disease activity (11, 62). Further understanding of all of the components of the IC transfer and uptake mechanism will provide the insight necessary to identify critical pathogenetic mechanisms and to potentially manipulate them to advantage.

Acknowledgments

We thank the staff at LEMSIP for assistance in performing the in vivo experiments and Ms. E. Wright (University of Virginia) for excellent technical assistance with the in vitro experiments. We also thank Dr. C. L. Christian for his continued support and Ms. P. B. Redecha for critically reviewing the manuscript.

This work was supported in part by grants AR-33062 (Dr. Kimberly), AI-24322 (Dr. Unkless), and AR-24083 (Dr. Taylor) from the National Institutes of Health, the Irvington Institute for Medical Research (Dr. Edberg), and the New York Chapter of the Arthritis Foundation.

References

ing by red blood cells, and release in serum: effect of DNA m.w. and conditions of antibody excess. J. Immunol. 133:2079–2084.